Gossamer BioGOSS
GOSS
About: Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Employees: 145
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
2,407% more call options, than puts
Call options by funds: $2.93M | Put options by funds: $117K
200% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 3 (+2) [Q1 2025]
167% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 9
21% more capital invested
Capital invested by funds: $155M [Q4 2024] → $187M (+$31.9M) [Q1 2025]
17% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 30
13% more funds holding
Funds holding: 105 [Q4 2024] → 119 (+14) [Q1 2025]
0.97% less ownership
Funds ownership: 75.62% [Q4 2024] → 74.65% (-0.97%) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
223%
upside
Avg. target
$7.33
491%
upside
High target
$10
706%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Goldman Sachs Paul Choi | 545%upside $8 | Buy Maintained | 16 May 2025 |
Wedbush Laura Chico | 223%upside $4 | Outperform Reiterated | 16 May 2025 |
HC Wainwright & Co. Patrick Trucchio | 706%upside $10 | Buy Reiterated | 18 Mar 2025 |
Financial journalist opinion
Neutral
Business Wire
1 week ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective June 5th, 2025, to three non-executive employees of non-qualified stock op.
Neutral
Seeking Alpha
4 weeks ago
Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript
Gossamer Bio, Inc. (NASDAQ:GOSS ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Bryan Giraudo - COO & CFO Faheem Hasnain - Co-Founder, CEO, President & Chairman Richard Aranda - Chief Medical Officer Caryn Peterson - EVP, Regulatory Affairs Bob Smith - Chief Commercial Officer Conference Call Participants Joseph Schwartz - SVB Leerink Andreas Argyrides - Oppenheimer Yasmeen Rahimi - Piper Sandler & Co. Paul Choi - Goldman Sachs Olivia Brayer - Cantor Patrick Trucchio - HC Wainwright Laura Chico - Wedbush Operator Good afternoon, ladies and gentlemen, and welcome to the Gossamer Bio Q1 2025 Earnings Call. I will now turn the program over to Bryan Giraudo, Chief Financial Officer and Chief Operating Officer.
Negative
Zacks Investment Research
1 month ago
Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates
Gossamer Bio (GOSS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.19 per share a year ago.
Neutral
Business Wire
1 month ago
Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 2025, and announced the closure of new patient screening for the ongoing registrational Phase 3 PROSERA Study.
Neutral
Business Wire
1 month ago
Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it will report its first quarter 2025 financial results on Thursday, May 15, 2025. In connection with the earnings release, Gossamer's management team will host a l.
Neutral
Business Wire
1 month ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective May 5, 2025, to three non-executive employees of non-qualified stock optio.
Neutral
Business Wire
1 month ago
Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present a poster at the American Thoracic Society (ATS) 2025 International Conference, taking place from May 16th through 21st, in San Francisco, Califor.
Neutral
Business Wire
2 months ago
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective April 7, 2025, to one non-executive employee of non-qualified stock option.
Negative
Zacks Investment Research
3 months ago
Gossamer Bio (GOSS) Reports Q4 Loss, Tops Revenue Estimates
Gossamer Bio (GOSS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago.
Neutral
Business Wire
3 months ago
Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December 31, 2024, and provided a business update. “As we close the book on 2024 and embrace the promise of 2.
Charts implemented using Lightweight Charts™